N/A
N=44
Effects of E-Cigarette Nicotine Content in Smokers (Nicotine Flux Study)
Electronic Cigarette Use
Bottom Line
View on ClinicalTrials.gov: NCT04332926 ↗Enrolled (actual)
44
Serious AEs
2.3%
Results posted
Feb 2025
Primary outcome: Primary: Effort for Product Puffs With Cross Product Progressive Ratio Task (CP-PRT) — 6.30; 6.38; 6.34; 5.94 Breakpoint (highest trial completed)
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Tobacco product administration and assessment, own brand cigarettes (Other); Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotine (Other); Tobacco product administration and assessment, ECIG 30 Watts, 8 mg/ml nicotine (Other); Tobacco product administration and assessment, ECIG 30 Watts, 15 mg/ml nicotine (Other); Tobacco product administration and assessment, ECIG 30 Watts, 30 mg/ml nicotine (Other)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Virginia Commonwealth University
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Effort for Product Puffs With Cross Product Progressive Ratio Task (CP-PRT) |
6.30; 6.38; 6.34; 5.94 | — |
| PRIMARY Breakpoint of Drug Purchase Task (DPT) |
1.23; 0.54; 0.96; 0.43; 0.49 | — |
| PRIMARY Effort for Product Puffs With Progressive Ratio Task (PRT) |
9.06; 7.69; 7.88; 7.31; 6.34 | — |
Summary
This study aims to better understand how e-cigarettes (ECIG) nicotine flux impacts several behavioral economic measures of abuse liability.
Eligibility Criteria
Inclusion Criteria
- healthy (determined by self-report)
- between the ages of 18-55
- willing to provide informed consent
- able to attend the lab and abstain from tobacco/nicotine as required and must agree to use designated products according to study protocol
Exclusion Criteria
- Women if they are breast-feeding or test positive for pregnancy (by urinalysis) at screening.
- Some study details about the eligibility criteria are purposely omitted at this time to preserve scientific integrity. Full details will be posted at the conclusion of the study.
Data sourced from ClinicalTrials.gov (NCT04332926). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.